Haematologica
(Jun 2021)
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation
Andrea Visentin,
Laura Bonaldi,
Gian Matteo Rigolin,
Francesca Romana Mauro,
Annalisa Martines,
Federica Frezzato,
Stefano Pravato,
Leila Romano Gargarella,
Maria Antonella Bardi,
Maurizio Cavallari,
Eleonora Volta,
Francesco Cavazzini,
Mauro Nanni,
Monica Facco,
Francesco Piazza,
Anna Guarini,
Robin Foà,
Gianpietro Semenzato,
Antonio Cuneo,
Livio Trentin
Affiliations
Andrea Visentin
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua
Laura Bonaldi
Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS, Padua
Gian Matteo Rigolin
Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara
Francesca Romana Mauro
Hematology division, Department of Precision and Translational Medicine, "Sapienza" University, Rome
Annalisa Martines
Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS, Padua
Federica Frezzato
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua
Stefano Pravato
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua
Leila Romano Gargarella
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua
Maria Antonella Bardi
Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara
Maurizio Cavallari
Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara
Eleonora Volta
Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara
Francesco Cavazzini
Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara
Mauro Nanni
Hematology division, Department of Precision and Translational Medicine, "Sapienza" University, Rome
Monica Facco
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua
Francesco Piazza
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua
Anna Guarini
Hematology division, Department of Precision and Translational Medicine, "Sapienza" University, Rome
Robin Foà
Hematology division, Department of Precision and Translational Medicine, "Sapienza" University, Rome
Gianpietro Semenzato
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua
Antonio Cuneo
Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara
Livio Trentin
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua
DOI
https://doi.org/10.3324/haematol.2021.278304
Journal volume & issue
Vol. 107,
no. 4
Abstract
Read online
Complex karyotype (CK) at chronic lymphocytic leukemia (CLL) diagnosis is a negative biomarker of adverse outcome. Since the impact of CK and its subtypes, namely type-2 CK (CK with major structural abnormalities) or high-CK (CK with ≥5 chromosome abnormalities), on the risk of developing Richter syndrome (RS) is unknown, we carried out a multicenter real-life retrospective study to test its prognostic impact. Among 540 CLL patients, 107 harbored a CK at CLL diagnosis, 78 were classified as CK2 and 52 as high-CK. Twenty-eight patients developed RS during a median follow-up of 6.7 years. At the time of CLL diagnosis, CK2 and high-CK were more common and predicted the highest risk of RS transformation, together with advanced Binet stage, unmutated (U)-IGHV, 11q-, and TP53 abnormalities. We integrated these variables into a hierarchical model: high-CK and/or CK2 patients showed a 10-year time to RS (TTRS) of 31%; U-IGHV/11q- /TP53 abnormalities/Binet stage B-C patients had a 10-year TTRS of 12%; mutated (M)-IGHV without CK and TP53 disruption a 10-year TTRS of 3% (P<0.0001). We herein demonstrate that CK landscape at CLL diagnosis allows the risk of RS transformation to be refined and we recapitulated clinico-biological variables into a prognostic model.
Keywords
Published in Haematologica
ISSN
0390-6078 (Print)
1592-8721 (Online)
Publisher
Ferrata Storti Foundation
Country of publisher
Italy
LCC subjects
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
Website
http://www.haematologica.org
About the journal
WeChat QR code
Close